Physiologic Changes of Posterior Ocular Segment During the Menstrual Cycle

NCT ID: NCT04731207

Last Updated: 2023-10-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

39 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-09-03

Study Completion Date

2023-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Changes of luteinizing hormone (LH), estrogen and progesterone during the menstrual cycle influence the ocular physiology in both anterior and posterior segments. From the literature review, there were no significant differentiation in tear physiology, anterior chamber dept, lens thickness and refractive status. Some studies demonstrated then the central corneal thickness was thinner in the follicular phase, but this is non-conclusive. Advance in ophthalmic technologies provide few studies of posterior segment changes during the menstrual cycle, however, there were quite difference in methodology such as detection methods of ovulation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

There were 2 studies of posterior segment changes during the menstrual cycle. Akar et al showed significant decrease of neuroretinal rim area and increase of cupt area in late luteal phase. Ulas et al found that choroidal thickness was significant thicker in mid-luteal phase. However, the study of retinal vascular density by optical coherence tomography angiography (OCTA) during the menstrual cycle has never been published before.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Retinal Vascular

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy pregnant women

All participants will be investigated by Optovue® in follicular phase, ovulatory phase, luteal phase of menstrual cycle. The investigation will be done between 12 PM and 1 PM at each phase. Urine pregnancy testing was done at first and last visits. LH ovulation test was performed by the participants own. if the ovulation was detected by urine strip test, the participant have to underwent the Optovue® within 48 hours.

Group Type OTHER

Optovue®

Intervention Type DEVICE

Optical coherence tomography and optical coherece tomography angiography

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Optovue®

Optical coherence tomography and optical coherece tomography angiography

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Female with age 25-40 yr
* Normal body mass index (18.5-24.9)
* Regular menstrual cycle (28-32 days)
* Written informed consent

Exclusion Criteria

* Pregnant women
* Lactating women
* Having childbirth or miscarriage within 6 months
* Systemic diseases which need taking the regular medication
* History of ocular disease such as glaucoma, retinal vascular diseases and macular disease
* History of hormonal taking such as oral contraceptive pills within 6 months
* History of intraocular laser and intraocular surgery
* Refractive error; spherical equivalent \>4 diopters
* Can not taking the images by Optovue® such as spine diseases

Withdrawal criteria

* Pregnancy detection during the study period
* Receiving sex hormone during the study period such as emergency contraceptive pills
Minimum Eligible Age

25 Years

Maximum Eligible Age

40 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Khon Kaen University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Suthasinee Sinawat

Associate Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Suthasinee Sinawat, MD

Role: PRINCIPAL_INVESTIGATOR

KKU Eye Center, Department of Ophthalmology, Faculty of Medicine, Khon Kaen University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Khon Kaen University

Khon Kaen, , Thailand

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Thailand

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Suthasinee Sinawat, MD

Role: CONTACT

+66 81 5454594

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Suthasinee Sinawat, MD

Role: primary

0815454594

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HE631585

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Retinal Investigation Using Optos OCT Device
NCT06846151 NOT_YET_RECRUITING NA
Adaptive Optics Retinal Imaging
NCT02317328 RECRUITING